Impact on cardiovascular events of increasing high density lipoprotein cholesterol with and without lipid lowering drugs

Heart

Volumn 92, Issue 6, 2006, Pages 746-751

  Wei, L ^b   Murphy, M J ^b   MacDonald, Thomas M ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PRIORITY JOURNAL; UNITED KINGDOM;

ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; COHORT STUDIES; FEMALE; HUMANS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 33744478897     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2005.068411     Document Type: Article

References (22)

1. Barr DP, Russ EM, Eder HA. Protein-lipid relationship in human plasma. Am J Med 1951;11:480-5.
2. Castelli WP, Garrison RJ, Wilson PW, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham study. JAMA 1986;256:2835-8.
3. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective cardiovascular Münster study. Am J Cardiol 1992;70:733-7.
4. Stampfer M, Sacks FM, Salvini S, et al. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 1991;325:373-81.
5. Simes RJ, Marschner IC, Hunt D, et al. Relationship between lipid levels and clinical outcomes in the long-term intervention with pravastatin in ischemic disease (LIPID) trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation 2002;105:1162-9.
6. Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation 1998;98:2513-9.
7. Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23). BMJ 1998;316:823-8.
8. Sacks FM. Expert Group on HDL Cholesterol. The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations, Am J Cardiol 2002;90:139-43.
9. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341:410-8.
10. Brousseau ME, Xchaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004;350:1505-15.
11. Evans JMM, MacDonald TM. The Tayside Medicines Monitoring Unit (MEMO). In: Strom BL, eds. Pharmacoepidemiology, 3rd edn. Chichester: John Wiley and Sons, 2000:361-74.
12. Dean BB, Borenstein JE, Henning JM, et al. Can change in high-density lipoprotein cholesterol levels reduce cardiovascular risk? Am Heart J 2004;147:966-76.
13. Vaughan G, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet 1996;348:1079-82.
14. Barbier O, Pineda Torra I, Duguay Y, et al. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 2002;22:717-26.
15. Anon. Smoking. In: Scottish health survey 1995, vol 1. Edinburgh: The Stationery Office, 1997:140-1.
16. Evans JM, Newton RW, Ruta DA, et al. Socio-economic status, obesity and prevalence of type 1 and type 2 diabetes mellitus. Diabet Med 2000;17:478-80.
17. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004;141:704-70.
18. Wei L, Wang J, Thompson P, et al. Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study. Heart 2002;88:229-33.
19. Mantel-Teeuwisse AK, Kloosterman JM, Maitland-van der Zee AH, et al. Drug-Induced lipid changes: a review of the unintended effects of some commonly used drugs on serum lipid levels. Drug Saf 2001;24:443-56.
20. LaRosa J, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35.
21. Cannon CP, Braunwald E, McCabe CH, et al. The Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504.
22. MacDonald TM, Morant SV, Robinson GC, et al. Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study. BMJ 1997;315:1333-7.